XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.25.3

Revision of Previously Issued Financial Statements | 9 Months Ended
--- | ---
Sep. 30, 2025
Accounting Changes and Error Corrections [Abstract] |
Revision of Previously Issued Financial Statements | Note 13. Revision of Previously Issued Financial Statements As discussed in “Note 1. Unaudited Condensed Consolidated Financial Statements,” the Company identified and corrected an immaterial error related to the classification of certain employee costs in the Cardiopulmonary segment between cost of sales and selling, general, and administrative expense in the consolidated statements of income (loss). The following tables present a summary of the corrections to the impacted financial statement line items in the Company’s financial statements previously issued in the Annual Report on Form 10-K and unaudited Quarterly Reports on Form 10-Q (in thousands):
|  | Twelve Months Ended December 31, 2024 |  | Twelve Months Ended December 31, 2023
| As Previously Reported |  | Adjustment |  | As Revised |  | As Previously Reported |  | Adjustment |  | As Revised
Cost of sales |  | $ | 382,564 |  |  | $ | 17,389 |  |  | $ | 399,953 |  |  | $ | 382,295 |  |  | $ | 15,430 |  |  | $ | 397,725 |
Gross profit |  | 870,873 |  |  | (17,389) |  |  | 853,484 |  |  | 771,250 |  |  | (15,430) |  |  | 755,820 |
Selling, general, and administrative |  | 526,265 |  |  | (17,389) |  |  | 508,876 |  |  | 518,129 |  |  | (15,430) |  |  | 502,699 |
|  | Three Months Ended March 31, 2025 |  | Three Months Ended March 31, 2024
| As Previously Reported |  | Adjustment |  | As Revised |  | As Previously Reported |  | Adjustment |  | As Revised
Cost of sales |  | $ | 96,080 |  |  | $ | 4,521 |  |  | $ | 100,601 |  |  | $ | 87,522 |  |  | $ | 4,182 |  |  | $ | 91,704 |
Gross profit |  | 220,775 |  |  | (4,521) |  |  | 216,254 |  |  | 207,390 |  |  | (4,182) |  |  | 203,208 |
Selling, general, and administrative |  | 133,667 |  |  | (4,521) |  |  | 129,146 |  |  | 129,863 |  |  | (4,182) |  |  | 125,681 |
|  | Three Months Ended September 30, 2024 |  | Nine Months Ended September 30, 2024
| As Previously Reported |  | Adjustment |  | As Revised |  | As Previously Reported |  | Adjustment |  | As Revised
Cost of sales |  | $ | 92,856 |  |  | $ | 4,235 |  |  | $ | 97,091 |  |  | $ | 280,088 |  |  | $ | 12,404 |  |  | $ | 292,492 |
Gross profit |  | 225,264 |  |  | (4,235) |  |  | 221,029 |  |  | 651,519 |  |  | (12,404) |  |  | 639,115 |
Selling, general, and administrative |  | 131,661 |  |  | (4,235) |  |  | 127,426 |  |  | 390,642 |  |  | (12,404) |  |  | 378,238 |
The following tables present a summary of the corrections to the impacted Cardiopulmonary disaggregated segment income table line items in “Note 17. Geographic and Segment Information” and “Notre 10. Geographic and Segment Information” previously included in the 2024 Annual Report on Form 10-K and in the unaudited March 31, 2025 Quarterly Report on Form 10-Q, respectively (in thousands):
|  | Twelve Months Ended December 31, 2024 |  | Twelve Months Ended December 31, 2023
| As Previously Reported |  | Adjustment |  | As Revised |  | As Previously Reported |  | Adjustment |  | As Revised
Cost of sales |  | $ | 316,937 |  |  | $ | 17,389 |  |  | $ | 334,326 |  |  | $ | 290,929 |  |  | $ | 15,430 |  |  | $ | 306,359 |
Selling, general, and administrative |  | 217,136 |  |  | (17,389) |  |  | 199,747 |  |  | 207,001 |  |  | (15,430) |  |  | 191,571 |
|  | Three Months Ended March 31, 2025 |  | Three Months Ended March 31, 2024
| As Previously Reported |  | Adjustment |  | As Revised |  | As Previously Reported |  | Adjustment |  | As Revised
Cost of sales |  | $ | 80,399 |  |  | $ | 4,521 |  |  | $ | 84,920 |  |  | $ | 72,097 |  |  | $ | 4,182 |  |  | $ | 76,279 |
Selling, general, and administrative |  | 58,480 |  |  | (4,521) |  |  | 53,959 |  |  | 50,745 |  |  | (4,182) |  |  | 46,563 |

X
- References No definition available. + Details
Name: | us-gaap_AccountingChangesAndErrorCorrectionsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting error correction. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7 + Details
Name: | us-gaap_ErrorCorrectionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration